Human polyclonal anti-hepatitis B surface antigen immunoglobulin reduces the frequency of acute rejection after liver transplantation for chronic hepatitis B

Authors

  • Claudia Alves COUTO University of São Paulo; School of Medicine; Liver Unit
  • Paulo Lisboa BITTENCOURT University of São Paulo; School of Medicine; Liver Unit
  • Alberto Queiroz FARIAS University of São Paulo; School of Medicine; Liver Unit
  • Margareth Pauli LALLEE University of São Paulo; School of Medicine; Liver Unit
  • Eduardo Luiz Rachid CANÇADO University of São Paulo; School of Medicine; Liver Unit
  • Paulo Celso Bosco MASSAROLLO University of São Paulo; School of Medicine; Liver Unit
  • Sérgio MIES University of São Paulo; School of Medicine; Liver Unit

Keywords:

HBIg, Acute hepatic rejection, Liver transplantation, Chronic hepatitis B

Abstract

BACKGROUND: Use of polyclonal anti-hepatitis B surface antigen immunoglobulin (HBIg) has been shown to reduce hepatitis B virus (HBV) recurrence after liver transplantation (LT) and to decrease the frequency of acute cellular rejection (ACR). However, the protective role of HBIg against ACR remains controversial, since HBV infection has been also associated with a lower incidence of ACR. AIM: To assess the relationship between HBIg immunoprophylaxis and the incidence of rejection after LT. METHODS: 260 patients (158 males, 43 ± 14 years old) submitted to LT were retrospectively evaluated and divided into three groups, according to the presence of HBsAg and the use of HBIg. Group I was comprised of HBsAg-positive patients (n = 12) that received HBIg for more than 6 months. Group II was comprised of HBsAg-positive patients that historically have not received HBIg or have been treated irregularly for less than 3 months (n = 10). Group III was composed of 238 HBsAg-negative subjects that have not received HBIg. RESULTS: HBIg-treated patients (group I) had significantly less ACR episodes, when compared to group II and III. No differences between groups II and III were observed. CONCLUSIONS: Long-term HBIg administration contributes independently to reduce the number of ACR episodes after LT.

Downloads

Download data is not yet available.

Downloads

Published

2001-12-01

Issue

Section

Hepatitis

How to Cite

COUTO, C. A., BITTENCOURT, P. L., FARIAS, A. Q., LALLEE, M. P., CANÇADO, E. L. R., MASSAROLLO, P. C. B., & MIES, S. (2001). Human polyclonal anti-hepatitis B surface antigen immunoglobulin reduces the frequency of acute rejection after liver transplantation for chronic hepatitis B . Revista Do Instituto De Medicina Tropical De São Paulo, 43(6), 335-337. https://revistas.usp.br/rimtsp/article/view/30560